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Haploidentical hematopoietic stem cell transplantation (HSCT) is an attractive alternative donor option based
on the rapid availability of an acceptable donor for most patients and decreased cost compared with costs of
other alternative donor strategies. The safety of haploidentical HSCT has increased in recent years, making it
ethically feasible to offer to patients with earlier stage disease. We developed a 2-step approach to hap-
loidentical HSCT that separates the lymphoid and myeloid portions of the graft, allowing ﬁxed T cell dosing to
improve consistency in outcome comparisons. In the initial 2-step trial, the subset of patients without
morphologic disease at HSCT had high rates of disease-free survival. To conﬁrm these results, 28 additional
patients without evidence of their disease were treated and are now 15 to 45 (median, 31) months past HSCT.
To date, the 2-year cumulative incidence of nonrelapse mortality is 3.6%, with only 1 patient dying of non-
relapse causes, conﬁrming the safety of this approach. Based on low regimen toxicity, the probabilities of
disease-free and overall survival at 2 years are 74% and 77%, respectively, consistent with the ﬁndings in the
initial trial and supporting the use of this approach in earlier stage patients lacking a matched related donor.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The availability of a suitable matched related donor for
patients undergoing allogeneic hematopoietic stem cell
transplantation (HSCT) has decreased in the last decade
because of downward trends in nuclear family size [1,2] and
an increase in the number of mixed parentage families,
especially in younger segments of the population [3].edgments on page 651.
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ty for Blood and Marrow Transplantation.Conversely, older patients are increasingly undergoing HSCT
but have limited matched related donor options [4] because
of advanced sibling age and comorbidities. Based on these
trends, there is a crucial need to safely treat patients
requiring HSCT using alternative donors.
Haploidentical HSCT is an attractive alternative donor
option for many reasons. Unlike HSCT using unrelated adult
donors or cord blood, there are no additional search, storage,
or transportation fees. The local selection and use of a hap-
loidentical donor avoids delays in treatment and there is
greater control of cell doses. Most patients will have a suit-
able haploidentical family donor, extending HSCT therapy to
almost every segment of the population, including minority
or mixed-ancestry patients, many of whom are unlikely to
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tries [5,6]. The expanded pool of prospective haploidentical
donors for each patient allows optimization of donor selec-
tion based on factors other than human leukocyte antigen
(HLA) matching, such as cytomegalovirus (CMV) serostatus,
gender differences, or killer immunoglobulin-like (KIR)
ligand mismatching [7].
Historically, outcomes after haploidentical HSCT have
been negatively affected by delayed post-HSCT immune re-
covery, a result of the necessity to attenuate T cells in the
mismatched graft to avoid life-threatening graft-versus-host
disease (GVHD) [8-10]. Recent advances in T cellecontaining
haploidentical approaches have improved immune recon-
stitution and outcomes [11]. However, the heterogeneity of
HSCT approaches, especially the variable dosing of T cells,
precludes the ability to compare outcomes among hap-
loidentical approaches and between haploidentical HSCT
versus HSCT using other donor sources.
Based on the goals of establishing a safe platform in
haploidentical HSCT and examining the impact of T cell
dosing on haploidentical HSCT outcomes, we developed a
myeloablative 2-step approach in which the lymphoid and
myeloid portions of the graft are administered separately to
control T cell dosing. In this approach, an unmanipulated
donor lymphocyte product (DLI), containing a ﬁxed dose of
2  108/kg T cells, is administered after a conditioning
regimen of 12 Gy total body irradiation. This quantity of T
cells was associated with high engraftment rates and a low
incidence of grades III and IV GVHD in the phase I portion of
the initial 2-step trial. Within approximately 24 hours of the
T cell infusion, an alloreaction consisting of high fever and, in
some cases rash and diarrhea, occurs. Two days later, cyclo-
phosphamide (CY) is administered to establish bidirectional
tolerance, based on the work of Mayumi et al. [12] and in-
vestigators at Johns Hopkins [13,14]. The symptoms associ-
ated with the alloreaction universally resolve after CY
treatment. The myeloid portion of the graft is given 24 hours
after the completion of CY. This 2-step regimen (Figure 1)
allows the administration of a ﬁxed dose of T cells, enhancing
the reproducibility of outcomes, and avoids the polarizing
effects of granulocyte colonyestimulating factor (G-CSF) on
donor T cells as growth factors are initiated after the DLI
collection. In addition, count recovery is more prompt
compared with in post-HSCT CY approaches, as the myeloid
portion of the graft is not exposed to CY [15].
In the initial phase I/II haploidentical 2-step trial, a
tolerized T cell dose of 2  108/kg was associated with low
rates of grades III and IV GVHD, consistent engraftment in
patients without donor-speciﬁc antibodies, and robust im-
mune reconstitution. Based on this low toxicity, the 12 pa-
tients without disease at the time of HSCT had a probabilityFigure 1. The 2-step regimen. Total body irradiation dose is 1.5 Gy per fraction, for
phenolate mofetil (MMF) are initiated on day 1 for GVHD prophylaxis.of overall survival (OS) of 75% at 3 years at the time of the
initial report [16].
The results of this ﬁrst trial suggested that the 2-step
approach to haploidentical HSCT was an appropriate pri-
mary alternate strategy for patients with earlier stage disease
who were without matched related donors. Although the 2-
step platform allows for the exploration of T cell dosing and
timing, potentially important strategies to increase disease-
free survival (DFS) rates in patients with resistant disease,
the goal of this particular second generation 2-step trial was
to conﬁrm the safety and efﬁcacy of this method in a larger
population of patients without evidence of their malignancy
at HSCT.METHODS
Recipient Consent, Eligibility, Donor Selection
Informed consent was obtained for all of the patients in accordancewith
the Declaration of Helsinki. The study was approved by the institutional
review board of Thomas Jefferson University. Patients had to be in
morphologic complete remission to be entered on trial; patients with active
disease were not eligible. Other major entry criteria included the availability
of a haploidentical related donor that was mismatched for  2 HLA antigens
(HLA-A, -B, -C, -DRB1) in the graft-versus-host direction, adequate organ
function as deﬁned by a creatinine clearance of> 60 mL/minute, pulmonary
diffusion capacity  50% (corrected for hemoglobin), cardiac ejection
fraction  50%, Karnofsky performance status (KPS)  80%, and a hemato-
poietic cell transplant comorbidity index (HSCT-CI) [17] score of  5. Pa-
tients were excluded if they were pregnant or had evidence of any type of
other malignancy. Donors were selected to try to maximize antihost allor-
eactivity, which was based on factors such as a higher degree of HLA
mismatch with the recipient, the presence of recipient/donor KIR ligand
mismatches as deﬁned by the Perugia group [18], the presence of a desirable
activating KIR haplotype in the donor where applicable [19], and gender
mismatches. No patient on trial had a donor-speciﬁc HLA antibody.Collection of Cells, Graft Characteristics, and Processing
Donors underwent apheresis for DLI collection on days -7 and -6. A
portion of the unmanipulated DLI product, which contained a ﬁxed dose of
2  108 kg of CD3þ cells, was infused after the last fraction of total body
irradiation on day -6. After completion of the DLI apheresis, donors received
subcutaneous injections of G-CSF, 5 mg/kg twice per day on days 5
through 1, and underwent additional aphereses for hematopoietic stem
cells (HSC) on days 2 and 1. The HSC product underwent CD34 selection
using the CliniMACS CD34 Reagent System (Miltenyi Biotec, Inc., Auburn,
CA). This device was used under Investigational Device Exemption #14336.
The targeted cell doses in the HSC product were 2 to 10  106/kg CD 34þ/kg
cells and  5  104/kg CD3þ/kg cells. Processing and infusion of the HSC
product occurred on day 0.Deﬁnitions
White cell engraftment was deﬁned as an absolute neutrophil count
of  .5  109/L for at least 3 consecutive days after transplantation. Platelet
engraftment was deﬁned as a platelet count of 20,000/mL without trans-
fusion for the 7 preceding days. Toxicities were graded using National
Cancer Institute Common Toxicity Criteria, Version 3.0. Acute GVHD was
scored based on the Glucksberg system [20]. Chronic GVHD was based on
the National Institutes of Health Consensus Criteria [21].a total dose of 12 Gy; CY dose is 60 mg/kg/day. Tacrolimus (Tacro) and myco-
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Patients were monitored weekly for CMV reactivation using a quanti-
tative CMV PCR assay performed on peripheral blood samples. If the test
became positive, patients were pre-emptively treated with foscarnet or
valganciclovir. Patients were given intravenous gamma globulin therapy
every 4 weeks until IgG levels returned to the normal range. Tacrolimus and
mycophenolate mofetil were started on day 1. Tacrolimus was adminis-
tered in divided doses 12 hours apart with an initial dose of .015 mg/kg on
day1, decreasing to .0075mg/kg/day beginning on day 0, and then titrated
to target a level of 8 ng/mL  2. The dose of mycophenolate mofetil was
2 grams administered in divided doses every 12 hours, which was dis-
continued on day þ28. GM-CSF 250 mcg/m2 was started on day þ1 and
continued until there was a self-sustaining absolute neutrophil count of
1.5  109/L. Patients with Philadelphia chromosomeepositive acute lym-
phocytic leukemia (Ph þ ALL) were restarted on their pre-HSCT tyrosine
kinase inhibitor (TKI), which in all cases was dasatinib, at a dose of 100 mg
daily until 1 year after HSCT, if tolerated.Statistical Analysis
The primary endpoint of the trial to prove efﬁcacy was 50% DFS at
1 year. Secondary objectives included assessment of OS, relapse-related
mortality (RRM), nonrelapse mortality (NRM), and acute and chronic
GVHD. OS and DFS were estimated using the Kaplan-Meier (product-limit)
method. DFSwas deﬁned as the probability of being alive and free of disease
at the time of analysis, and therefore death or disease relapse were treated
as events. Cumulative incidence calculations were used to estimate the
probability of grades II to IV GVHD, grades III and IV GVHD, and chronic
GVHD with death as a competing risk. Cumulative incidence of NRM was
calculated with RRM as a competing risk. Cumulative incidence of RRM was
calculated with death from other causes as a competing risk. Competing risk
analysis was done using the freely available EZR software version 1.24 [22].
All other analyses were performed in SPSS version 21 and SAS 9.1 (SAS
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1, nucleophosmin-1 mutation; AA, African American; MDS, myelodysplastic syndr
B haplotypes: Only 1 patient with AML/MDS received cells from a favorable activa
* Indicates the recipient was genotypically homozygous for HLA C1 alleles and t
y Indicates the recipient was genotypically negative for HLA Bw4 alleles and th
mozygous for HLA C2 group alleles.RESULTS
Patients
Thirty consecutive patients were enrolled on this trial.
There were 2 late screening failures, both related to evi-
dence of recurrent disease at the time of admission for
HSCT. These patients were replaced to meet the accrual goal
of the trial of 28 patients. The 28 treated patients (Table 1)
had a median age of 47 (range, 21 to 65) years, with di-
agnoses of acute myelogenous leukemia (AML) (n ¼ 15),
preeB cell acute lymphoblastic leukemia (ALL) (n ¼ 4),
Philadelphia chromosomeepositive B cell ALL (n ¼ 4), T cell
ALL (n ¼ 2), myelodysplastic syndrome (n ¼ 1), mantle cell
lymphoma (n ¼ 1), and hepatosplenic T cell lymphoma
(n ¼ 1). No patient had morphologic evidence of disease at
the time of HSCT. One patient with AML had a persistent
deletion of chromosome 9 by FISH at the time of HSCT.
Three patients with AML had detectable FMS-like tyrosine
kinase-3 (FLT-3) mutations by PCR at diagnosis. FLT-3
mutational status was not tested at the time of HSCT in 2
patients treated earlier on the trial. The third patient, who
also found to be positive for the nucleophosmin-1 mutation
by PCR at diagnosis, had no evidence of either of these
mutations by PCR at the time of HSCT. Patients and donors
were mismatched for 4 (n ¼ 15), 3 (n ¼ 9), or 2 (n ¼ 4) HLA-
A, -B, -C, or -DRB1 antigens in the GVHD direction. All pa-
tients had a KPS of 90%. The median HCT-CI score was
2 (range, 0 to 5) points. Median follow-up of the cohort is
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Table 2
Graft Characteristics
Step 1 Step 2
CD3þ/kg  108 CD 34þ/kg  106 Residual CD3þ cells/kg
in CD34þ product  103
2.0 (all patients) 5.08 (2.88-10.0) 3.47 (2.0-20.9)
Data presented are median (range).
Figure 3. CMV reactivation and day þ90 immune reconstitution. Patients with
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All patients received the targeted cell doses in the DLI and
HSC products (Table 2). There were no graft failures. All pa-
tients engrafted white cells at a median of 11 (range, 9 to 13)
days after HSCT. All patients engrafted platelets at a median
of 17 (range, 13 to 24) days after HSCT.CMV reactivation had higher numbers of CD3/4, CD3/8, and NKDim cells at
dayþ90 than patients without CMV reactivation. Differences were the greatest
in the CD3/8 populations (P ¼ .000, Mann-Whitney).NRM
The 100-daymortality on the studywas 0%. Only 1 patient
died of nonrelapse causes. A 27-year-old patient under
evaluation for a persistent fever died of a subdural hemor-
rhage, which occurred a few hours after a diagnostic lumbar
puncture. No patient died from GVHD or infection. The cu-
mulative incidence of NRM at 2 years is 3.6% (Figure 2).Immune Reconstitution and Infection
Immune recovery was robust, with median CD3/4 and
CD3/8 counts of 73.7 and 48.4 and 148 and 154.8 cells/mL
respectively at days þ28 and þ90. Natural killer cell (NK)dim
recovery was also brisk at 113 and 154.5 cells/mL at days þ28
and þ90, respectively. No patients died of infection. CMV
reactivation occurred in 10 of 19 patients inwhich the donor,
recipient, or both were CMV positive. There were no new
primary CMV infections in CMV negative/negative trans-
plantation combinations and no detectable CMV tissue dis-
ease in any of the patients. Quantitative recovery of CD3/4,
CD3/8, and NKdim populations was greater in patients who
reactivated CMV, with the greatest differences observed in
the CD3/8 population. The median CD3/8 count at day þ 90
in patients who developed CMV reactivation was 494.8
versus 58.8 cells/mL in patients without CMV reactivation,
with equal amounts of steroid use in each group (Figure 3).Figure 2. Relapse and nonrelapse mortality. Cumulative incidences of death
from relapse and nonrelapse causes.GVHD
The cumulative incidences of grades II to IV and III and IV
acute GVHD were 39.3% and 3.6%, respectively, at 2 years
(Figure 4). Most of this incidence was due to single-organ
stage III grade II acute skin GVHD, which occurred in 25%
of patients. Skin GVHD responded quickly to steroids or
steroids plus photopheresis.
The cumulative incidence of chronic GVHD was 22% at
2 years. Chronic GVHD occurred in 6 of 28 (21%) of patients.
The most severe chronic GVHD (score of 3) occurred in 2
patients with oral/ocular and gut manifestations. One of
these patients ultimately died from relapse; the second pa-
tient had near resolution of gut symptoms and is completing
a steroid taper. One of the 6 patients (score of 2) is
completing treatment with photopheresis for skin GVHD.
Two patients developed ocular GVHD (scores of 1 and 2) and
required intermittent local therapy. One patient with oral
GVHD (score of 1) had resolution of symptoms and is no
longer being treated. No patients to date have developed
sclerodermoid GVHD.
Of the group of patients who were alive and disease free
at 6 and 12 months after HSCT, 16 of 27 (59%) and 17 of 22
(77%), respectively, were off all systemic immunosuppres-
sion, including steroids. Seventeen of 22 patients are at leastFigure 4. Cumulative incidence acute GVHD.
Figure 5. OS of initial versus follow-up 2-step trials. To date, the OS rate in the
follow-up 2-step trial recapitulates the ﬁndings of the initial 2 step trial in a
larger patient population.
D. Grosso et al. / Biol Blood Marrow Transplant 21 (2015) 646e6526502 years after HSCT. All of these patients, 17 of 17 (100%), are
off systemic immunosuppression.
Treatment-Related Events
After infusion of the large dose of donor T cells in step 1 of
the HSCT, patients developed high fevers (median, 103.6F;
range, 99.4 to 105.2) and, in some cases, rash and diarrhea
within approximately 24 hours of the DLI. This period of
“haploimmunostorm” was well tolerated in most of the pa-
tients, although the last patient on trial required a short
course of low-dose norepinephrine for hypotension, which
developed during this time period. The patient suffered no
adverse sequelae from this event.
Two patients developed grade II cystitis at days þ4
and þ14 after the last dose of CY, associated with BK virus in
the urine in 1 of the patients. Both had limited courses of the
cystitis and were treated with supportive care. A third pa-
tient developed grade III cystitis with symptoms starting
11 days after the last dose of CY. The cystitis was associated
with high levels of BK virus in the urine. The patient was
treated with continuous bladder irrigation, ciproﬂoxacin,
and cidofovir, and the symptoms resolved completely
approximately 1 month after the onset.
Dasatinib 100 mg twice daily was resumed in all 4 pa-
tients with Ph þ ALL. The drug was tolerated by only 1 pa-
tient who received it as planned until 1 year after HSCT.
Dasatinib was stopped after 5 days, 16 days, and 4 months of
therapy in the remaining 3 patients for severe vomiting,
pulmonary embolism and pancytopenia, and presumed renal
toxicity.
Except for the 1 patient who died of toxicity, all patients
were discharged to their homes after a median trans-
plantation admission length of 30 (range, 24 to 45) days. One
patient with T cell ALL, with a history of positive respiratory
PCR cultures for rhino/enterovirus, developed a syndrome
most resembling acute disseminated encephalomyelitis that
was associated with acute transverse myelitis and was
acutely readmitted to the hospital on day þ109. The en-
cephalitis resolved rapidly with steroids, but the patient
required several months of therapy for acute transverse
myelitis. The patient ultimately regained full function and
has returned to all activities of daily living.
DFS and OS
The median follow-up among the surviving patients is
31 months. Of the 28 patients treated, 6 patients developed
relapsed disease and 5 of these patients died of their ma-
lignancy. The probability of DFS at 1 and 2 years is 78.6% (95%
conﬁdence interval, 58.4% to 89.8%) and 74% (95% conﬁdence
interval, 52.7% to 86.7%), respectively, exceeding the primary
endpoint of the trial. The 5 patients who died of their disease
relapsed at a median of 270 (range, 97 to 356) days after
HSCT. Three of 5 maternal recipients developed relapsed
disease after treatment, consistent with the ﬁnding of
maternal recipients being at higher risk for relapse observed
in the initial trial. One of the maternal recipients with Ph þ
ALL was intolerant to post-HSCT TKI therapy and developed
relapsed disease 571 days after HSCT. The patient was treated
with chemotherapy, after which a TKI was reintroduced. This
patient is currently alive without molecular evidence of
disease 33 months after HSCT. All other surviving patients
have had no evidence of their disease since HSCT. The
probability of OS at 1 and 2 years was 89.3% and 77.3%,
respectively. There were no trends for improved DFS based
on KIR ligandmismatching or the use of donors with group BKIR haplotypes in this small group. Cumulative incidence of
RRM at 2 years was 19.2% (Figure 2).DISCUSSION
In the initial 2-step myeloablative haploidentical trial
[16], the 12 of 27 patients without evidence of disease at the
time of HSCT had an OS of 75% at 3 years. In this follow-up
trial, the 2-year probabilities of DFS and OS were similar,
conﬁrming the efﬁcacy and tolerability of this approach in a
larger group of patients with controlled disease (Figure 5).
Relapsed disease was the sole cause of mortality in the 27 of
28 patients surviving to discharge, highlighting the low
toxicity associated with the regimen and supporting the use
of haploidentical HSCT as a safe alternative-donor approach
in this subset of patients.
The low NRM rate was due to the absence of mortality
from rejection, infection, and GVHD. Despite the myeloa-
blative conditioning and the high dose of T cells used in this
approach, 2 patients in our initial trial with antidonor anti-
bodies suffered graft rejection. In this trial, no patient had an
HLA antibody against donor antigens, resulting in 100%
engraftment.
Quantitative recovery of T cell subsets and NK cells was
brisk. The lack of infectious death suggests that there was
qualitative recovery, as well. Interestingly, we noted in-
creases in the CD3/8 counts of patients in which CMV reac-
tivated, in some cases into the thousands within the ﬁrst
3 months of HSCT. Although the link between CMV reac-
tivation and CD3/8 counts was very strong, areas of future
research include the documentation of CMV-speciﬁc T cells
responses, as well as assessment of the potential impact, if
any, that immune response to CMV has on other outcomes,
such as relapse or GVHD, in a larger group of patients.
CY tolerization is consistently associated with both low
rates of grades III and IV acute GVHD and extensive chronic
GVHD across the 2-step protocols at our institution. Patients
on the current trial fared well in this regard, with 13 of 28
patients (46%) of patients having no acute GVHD at all, and
only 1 patient having grade III acute GVHD.
Eligibility criteria for the 2-step clinical trials has become
more stringent as we have gained experience with the
regimen and sought to reduce morbidity associated with this
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creates challenges in terms of optimal ﬂuid management.
These events appear to be associated with vasodilatation, not
unlike other syndromes associated with brisk cytokine
release. Aggressive hydration, including positive ﬂuid bal-
ance, appears to be appropriate supportive care during this
interval. The haploimmunostorm is followed immediately by
CY, an agent that can temporarily decrease ejection fraction
in some patients, further exacerbating ﬂuid balance issues.
Organ function, KPS, and HCT-CI criteria were optimized to
account for the rigor of this treatment approach in this and
other later generation 2-step trials to increase patient safety.
Based on our experience with the current subset of patients,
the updated criteria have been successful.
One of the patients with T cell ALL treated on this trial
developed a central nervous system (CNS) inﬂammatory
demyelinating disorder (IDD) about 3 months after HSCT.
Literature regarding risk factors for the development of CNS
IDDs after HSCT is limited, although 1 of the larger reports
identiﬁed the use of a mismatched donor, a diagnosis of ALL,
and an infectious history as risk factors for the development
of a CNS IDD [23]. Based on this data, our patient was at
higher risk for CNS IDD and has fortunately recovered
completely from the episode. Nevertheless, the development
of CNS IDDs may be associated with mismatched donor
HSCT. Given the increased application of haploidentical
HSCT, as well as the growing population of patients surviving
it, the incidence of CNS IDDsmay increase. Patients should be
carefully monitored for this condition, as early intervention
can avoid permanent disability.
Relapsed disease was the primary cause of death in pa-
tients treated on this trial. None of the 12 patients in com-
plete remission treated on the initial trial, and only 1 patient
on the current trial, developed relapsed malignancy more
than 12 months after HSCT. Therefore, as all patients are
more than 15 months after HSCT, we are cautiously opti-
mistic that the current DFS rate will not signiﬁcantly change
with additional follow-up time.
It is expected that OS rates, in the setting of a well-
tolerated regimen, would be superior in patients with
earlier stage disease compared with those with later or
resistant disease at HSCT. However, a signiﬁcant percentage
of patients treated on this trial had cytogenetic and molec-
ular ﬁndings (Table 1) that would have predicted a higher
relapse rate than what was observed.
The lower than expected RRM was potentially due to
other factors unrelated to disease status. The use of hap-
loidentical T cells at doses of 1 to 2  108 kg, such as those
used in the 2-step approach, have been associated with
antitumor effects in patients with leukemia and lymphoma
[24,25], suggesting that this dose of T cells may be important
and efﬁcacious in the haploidentical setting. In addition, G-
CSFeinduced polarization of donor T cells to type 2 re-
sponses, which favors tolerance, is avoided in this approach,
as the DLI is collected before the initiation of growth factor.
GM-CSF is used after HSCT in patients to further prevent this
type 2 lymphocyte skewing. We also noted a propensity for
maternal recipients to relapse in the ﬁrst trial, possibly based
on immune tolerance established at pregnancy. We avoided
selecting offspring donors for mothers whenever possible,
which may have decreased relapse rates. Indeed, in the
current trial, 3 of 5 maternal recipients who underwent
transplantation from their offspring because of the lack of
parental or sibling donors relapsed, further supporting this
observation. As we gained experience with the 2-stepapproach in prior trials, we noted that relapsed disease,
and not mortality from GVHD, was the primary reason for
treatment failure. Based on this observation, we instituted an
early tacrolimus taper in patients without active GVHD.
Decreased exposure to immunosuppressive agents has been
correlated with lower relapse rates [26,27], supporting a
potential beneﬁt for this strategy. Finally, the donor selection
approach of maximizing antihost alloreactivity may have
supported a stronger graft-versus-leukemia effect, although
this cannot be conﬁrmed without a larger group of patients
enabling multivariate analyses.
The 2-step approach to haploidentical HSCT appears to be
a safe and efﬁcacious alternative donor option for patients
with earlier stage disease. Based on the outcomes of this trial,
haploidentical HSCT using the 2-step approach remains the
alternative donor strategy of choice at our institution.ACKNOWLEDGMENTS
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